16 Mar 2020 07:00
Arix Bioscience Plc - Director/PDMR ShareholdingArix Bioscience Plc - Director/PDMR Shareholding
PR Newswire
London, March 13
ARIX BIOSCIENCE PLC
Director/PDMR Shareholding
LONDON, 13 March 2020: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces a conditional share award to Jonathan Peacock, Chairman, relating to his service in 2019 as an Executive Director. The award is subject to performance conditions over a three year assessment period, consistent with the awards made to other Executive Directors in 2019, as detailed on page 70 of the Annual Report and Accounts.
| PDMR DEALING NOTIFICATION | |||
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Jonathan Peacock | |
| 2 | Reason for the notification | ||
| a) | Position / status | Chairman | |
| b) | Initial notification / Amendment | Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Conditional share award | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 231,348 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 12 March 2020 | |
| f) | Place of the transaction | Outside a trading venue | |
For further information:
Robert Lyne Chief Operating Officer and General Counsel +44 (0)207 290 1050
- Ends -